At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 Feb 2000 No-Development-Reported for Cancer in Canada (Unknown route)
- 24 Mar 1997 Preclinical development for Cancer in Canada (Unknown route)